Insights From Technical Analysis

Racura Oncology (ASX: RAC): CEO Keeps Buying near 52-Week Lows as MYC Cancer Drug Advances

Sep 30, 2026

Proactive Equities Team

Racura Oncology's CEO-owned Nucleics added 23,000 shares near a 52-week low, while new data backs the company's MYC-silencing cancer drug ahead of a November Singapore conference.

Read more

Metallium (ASX: MTM): Texas FJH Scale-Up Advances Critical Metals Recovery

Sep 30, 2026

Proactive Equities Team

Metallium (ASX: MTM) is scaling its Flash Joule Heating technology in Texas, supported by US government funding, recent capital raising and supply agreements aimed at advancing critical metals recovery and commercialisation.

Read more

Codan (ASX: CDA): Trading Update Fuels a Breakout to Record Highs

Sep 29, 2026

Proactive Equities Team

Codan (ASX: CDA) hit record highs following a strong FY26 and upbeat FY27 outlook. Driven by robust Communications and Minelab growth, the stock surged 23.9%. Despite technical overextension, market momentum remains high, fuelled by solid order intake and earnings visibility.

Read more

Megaport (ASX: MP1): AI Clients Pre-Pay A$323M, Turning GPU Bets into Bankable Growth

Sep 29, 2026

Proactive Equities Team

Megaport (ASX: MP1) secures three AI infrastructure contracts, with customers prepaying about A$323 million, and lifts FY27 revenue and margin guidance as its Latitude.sh compute arm scales alongside a growing network business.

Read more

LTR Pharma (ASX: LTP): Where Revenue Growth Must First Survive the Clinical Test

Sep 29, 2026

Proactive Equities Team

LTR Pharma is moving towards commercialisation, with a targeted ROXUS US launch and SPONTAN Phase III trial. A scenario-based valuation suggests A$2.28 per share, but clinical, regulatory and funding risks remain significant. The chart shows consolidation below resistance.

Read more

BrainChip Holdings(ASX: BRN): Akida Neuromorphic AI Advances Edge Computing Across Strategic Markets

Sep 29, 2026

Proactive Equities Team

BrainChip (ASX: BRN) is advancing its Akida neuromorphic AI technology through developments in low-power Edge AI processing, strategic partnerships, and applications across healthcare, defence, aerospace, and industrial sectors.

Read more